KRKerstin J. Rolfe

Kerstin J. Rolfe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kerstin J. Rolfe has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Skin Regeneration: The Possibilities

    by Jack Penn, Addie O. Grobbelaar, Kerstin J. Rolfe

    • 1 November 2010
      • Vol. 11  (11) , 1221-8

    The growth receptors and their role in wound healing.

    by Kerstin J Rolfe, Adriaan Grobbelaar

    Abnormal wound healing is a major problem in healthcare today, with both scarring and chronic wounds affecting large numbers of individuals worldwide. Wound healing is a complex process involving several variables, including growth factors and their receptors. Chronic wounds fail to complete the wound healing process, while scarring is considered to be an overzealous wound healing process. Growth factor receptors and their ligands are being investigated to assess their potential in the development of therapeutic strategies to improve wound healing. This review discusses potential therapeutics for manipulating growth factors and their corresponding receptors for the treatment of abnormal wound healing.


  • Transforming growth factor β1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance

    by B R Klass, A O Grobbelaar, K J Rolfe

    Transforming growth factor β1 (TGFβ1) is a multifunctional cytokine known to be involved in a number of human diseases. It is believed to play an important role in wound healing and repair, as it is a key regulator of the production and remodelling of the extracellular matrix through its effect on mesenchymal cells. Over the last few years, it has become evident that the signalling pathway of TGFβ is complex with numerous receptor–ligand interactions, intracellular pathways and a number of mechanisms, which not only control the signalling but may also decide the response to the TGFβ signal. This review focuses on TGFβ1 signalling and the role that TGFβ1 plays in wound healing, repair and scarring.


  • Differential gene expression in response to transforming growth factor‐β1 by fetal and postnatal dermal fibroblasts

    by Kerstin J. Rolfe, Laurie M. Irvine, Addie O. Grobbelaar, Claire Linge

    The multipotent growth factor transforming growth factor (TGF)‐β1 is consistently linked with fibrosis and scarring. The perfect (scarless) healing of cutaneous wounds in early gestational age fetuses is proposed to be due to this tissue's predominance of the TGF‐β3 isoform over the profibrotic TGF‐β1 and 2. Nevertheless, TGF‐β1 is present during wound healing in the early fetus and recently we demonstrated that relevant intracellular signaling pathways are activated (albeit transiently) on TGF‐β1stimulation. This study aimed to determine whether TGF‐β1 has different effects on gene transcription in human fetal (<14 weeks) vs. human postnatal dermal fibroblasts, using real‐time polymerase chain reaction. The regulation pattern of a number of TGF‐β response genes differed dramatically between the two cell sources. The typical autocrine loop of TGF‐β1 autoinduction did not occur in fetal fibroblasts and genes that are normally up‐regulated, connective tissue growth factor and collagen type I were actually down‐regulated. Furthermore, other response genes responded in a delayed fashion (TGF‐β3) compared with that seen in the more developmentally mature postnatal fibroblasts. Finally, genes unaltered by TGF‐β stimulation in postnatal cells, TGF‐β2 and collagen III, were up‐regulated in fetal cells. These developmentally related differences in fibroblast response to TGF‐β1 may influence wound‐healing outcome, i.e., perfect regeneration or fibrosis.


  • Open Access

    Dermal fibroblasts derived from fetal and postnatal humans exhibit distinct responses to insulin like growth factors

    by Kerstin J Rolfe, Alison D Cambrey, Janette Richardson, Laurie M Irvine, Adriaan O Grobbelaar, Claire Linge

    Background: It has been well established that human fetuses will heal cutaneous wounds with perfect regeneration. Insulin-like growth factors are pro-fibrotic fibroblast mitogens that have important roles in both adult wound healing and during development, although their relative contribution towards fetal wound healing is currently unknown. We have compared responses to IGF-I and -II in human dermal fibroblast strains derived from early gestational age fetal (<14 weeks) and developmentally mature postnatal skin to identify any differences that might relate to their respective wound healing responses of regeneration or fibrosis. Results: We have established that the mitogenic response of fetal cells to both IGF-I and -II is much lower than that seen in postnatal dermal fibroblasts. Further, unlike postnatal cells, fetal cells fail to synthesise collagen in response to IGF-I, whereas they do increase synthesis in response to IGF-II. This apparent developmentally regulated difference in response to these related growth factors is also reflected in changes in the tyrosine phosphorylation pattern of a number of proteins. Postnatal cells exhibit a significant increase in phosphorylation of ERK 1 (p44) in response to IGF-I and conversely the p46 isoform of Shc on IGF-II stimulation. Fetal cells however only show a significant increase in an unidentified 100 kDa tyrosine-phosphorylated protein on stimulation with IGF-II. Conclusion: Dermal fibroblasts exhibit different responses to the two forms of IGF depending on their developmental maturity. This may relate to the developmental transition in cutaneous wound healing from regeneration to fibrosis.


  • A Role for TGF-β1-Induced Cellular Responses during Wound Healing of the Non-Scarring Early Human Fetus?

    by Kerstin J. Rolfe, Janette Richardson, Charlotte Vigor, Laurie M. Irvine, Addie O. Grobbelaar, Claire Linge


    • 1 May 2007
      • Vol. 52  (5) , 379-84

    Is localized, provoked vulvodynia an inflammatory condition?

    by Lois J Eva, Kerstin J Rolfe, Allan B MacLean, Wendy M N Reid, Anne Christine Wong Te Fong, Julie Crow, Christopher W Perrett

    To perform a pilot study to investigate the relationship between localized, provoked vulvodynia of the vestibule and inflammatory cytokine expression. Women with a diagnosis of localized, provoked vulvodynia had tissue samples taken for vulvar expression of Interleukin 1alpha and 1beta and tumor necrosis factor alpha and compared to those of a control group. The study group did not show a significant increase in expression of inflammatory markers. There was no evidence in this study that localized, provoked vulvodynia is an inflammatory condition, as previously thought. This may be helpful in explaining why some women are resistant to medical or antiinflammatory treatment and may allow treatment to be prescribed more effectively.


  • Open Access

    TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva

    by K J Rolfe, A B MacLean, J C Crow, E Benjamin, W M N Reid, C W Perrett

    Non-neoplastic epithelial lesions of the vulva (NNEDV) lichen sclerosus (LS) and squamous hyperplasia (SH) have been implicated in the pathogenesis of squamous cell carcinoma of the vulva (SCC). To date, there have been no recognisable precursor lesions for SCC associated with NNEDV. TP53 is the most frequent genetic change in human cancers and can indicate both aetiology and molecular pathogenesis of tumours. A total of 27 SCC patients underwent immunohistochemistry (IHC) and TP53 mutational analysis using microdissection and direct sequencing. There were 19 patients with areas of adjacent epidermis: 17 had NNEDV (four SCCs had more than one adjacent lesion) and two had normal epidermis. In all, 70.4% of the SCCs, 40% LS and 22.2% SH demonstrated overexpression of p53. In total, 77.8% of SCCs, 46.7% of LS and 22.2% SH demonstrated mutations in TP53, with the majority of lesions having a mutation in codon 136. Eight cases were identified where the same mutation was identified in the SCC and in the adjacent area. These data suggest that TP53 mutations develop in NNEDV and are intrinsic to the clonal evolution that leads to SCC. The type of mutation detected is more likely to occur due to endogenous cellular changes rather than exogenous carcinogen exposure.


    • 17 May 2002
      • Vol. 22, 857-61

    The role of vascular endothelial growth factor-A (VEGF-A) and platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) in Paget's disease of the vulva and breast.

    by Patricia E Ellis, Lan Fong Wong Te Fong, Kerstin J Rolfe, Julie C Crow, Wendy M N Reid, Tim Davidson, Allan B MacLean, Christopher W Perret

    Paget's disease of the vulva and the breast are uncommon conditions. The pathogenesis underlying these diseases is still unclear. Vascular endothelial growth factor-A (VEGF-A), a potent angiogenic factor, has been demonstrated in a variety of tumour cell types and is thought to be involved in tumour expansion. Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) has also been shown to stimulate angiogenesis. Fifty-four cases of Paget's disease of the vulva, including 10 with an associated invasive adenocarcinoma, and 38 cases of Paget's disease of the breast, including 26 with available associated ductal carcinoma in situ (DCIS) and/or invasive carcinoma of the breast, were evaluated immunohistochemically for the expression of VEGF-A and PD-ECGF/TP. VEGF-A was not expressed in Paget's disease of the vulva or breast. PD-ECGF/TP was expressed in 22 out of 54 (41%) cases of Paget's disease of the vulva. Four of the cases associated with invasive disease (40%) expressed PD-ECGF/TP. Twenty-one out of 38 (55%) cases of Paget's disease of the breast were positive for PD-ECGF/TP. Our data suggest that PD-ECGF/TP may have a role to play in the pathogenesis of Paget's disease of the vulva and the breast. The role of VEGF-A in Paget's disease of the vulva and the breast remains to be fully elucidated.